Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol

The development of acquired resistance to osimertinib (Osim) (AZD9291 or TAGRISSOTM), an FDA‐approved third‐generation epidermal growth factor receptor (EGFR) inhibitor for the treatment of EGFR‐mutant nonsmall cell lung cancer (NSCLC), limits the long‐term benefits for patients. Thus, effective tre...

Full description

Bibliographic Details
Main Authors: Hongjing Zang, Guoqing Qian, Jack Arbiser, Taofeek K. Owonikoko, Suresh S. Ramalingam, Songqing Fan, Shi‐Yong Sun
Format: Article
Language:English
Published: Wiley 2020-04-01
Series:Molecular Oncology
Subjects:
acquired resistance
apoptosis
EGFR
honokiol
lung cancer
osimertinib
Online Access:https://doi.org/10.1002/1878-0261.12645

Internet

https://doi.org/10.1002/1878-0261.12645

Similar Items